{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:19Z","timestamp":1792724779507,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03282-2","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T10:02:19Z","timestamp":1727776939000},"page":"126-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-0336","authenticated-orcid":false,"given":"Jing","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-1076","authenticated-orcid":false,"given":"Samuel","family":"Seery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taochao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-5021","authenticated-orcid":false,"given":"Fangrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiecheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-5871","authenticated-orcid":false,"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"3282_CR1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey, D. T. & Pui, C. H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 20, 142\u2013154 (2019).","journal-title":"Lancet Oncol."},{"key":"3282_CR2","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt, B. et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J. Clin. Oncol. 27, 3363\u20133369 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3282_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia (Version 1. 2020) (National Comprehensive Cancer Network, (2020); www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"3282_CR4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader, P. et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J. Clin. Oncol. 27, 377\u2013384 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3282_CR5","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J. Clin. Oncol. 39, 3340\u20133351 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3282_CR6","doi-asserted-by":"crossref","unstructured":"Wang, X. X. et al. Abstract CT052: clinical safety and efficacy study of TruUCAR\u2122 GC027: the first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL). Cancer Res. 80, CT052 (2020).","DOI":"10.1158\/1538-7445.AM2020-CT052"},{"key":"3282_CR7","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140, 321\u2013334 (2022).","journal-title":"Blood"},{"key":"3282_CR8","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood-2021-147632","volume":"138","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. The impact of the immunophenotyping characteristics of patients\u2019 peripheral blood on the manufacturing and clinical outcome of CD7-targeted chimeric antigen receptor T cells. Blood 138, 3830 (2021).","journal-title":"Blood"},{"key":"3282_CR9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","volume":"27","author":"S Li","year":"2021","unstructured":"Li, S. et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin. Cancer Res. 27, 1242\u20131246 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3282_CR10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","volume":"134","author":"LC Hill","year":"2019","unstructured":"Hill, L. C. et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies. Blood 134, 199 (2019).","journal-title":"Blood"},{"key":"3282_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2008.11.007","volume":"8","author":"A Dalloul","year":"2009","unstructured":"Dalloul, A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun. Rev. 8, 349\u2013353 (2009).","journal-title":"Autoimmun. Rev."},{"key":"3282_CR12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin, M. et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983\u2013992 (2015).","journal-title":"Blood"},{"key":"3282_CR13","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2023.41.16_suppl.7002","volume":"41","author":"LC Hill","year":"2023","unstructured":"Hill, L. C. et al. Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL. J. Clin. Oncol. 41, 7002 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3282_CR14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.201948309","volume":"50","author":"F Alotaibi","year":"2020","unstructured":"Alotaibi, F. et al. CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity. Eur. J. Immunol. 50, 695\u2013704 (2020).","journal-title":"Eur. J. Immunol."},{"key":"3282_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136860","volume":"136","author":"I Chun","year":"2020","unstructured":"Chun, I. et al. CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells. Blood 136, 51\u201352 (2020).","journal-title":"Blood"},{"key":"3282_CR16","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","volume":"29","author":"Z Dai","year":"2021","unstructured":"Dai, Z. et al. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol. Ther. 29, 2707\u20132722 (2021).","journal-title":"Mol. Ther."},{"key":"3282_CR17","first-page":"PO.20.00257","volume":"4","author":"R Lin","year":"2020","unstructured":"Lin, R., Zhou, Y., Yan, F., Li, D. & Yuan, Y. BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis. Oncol. 4, PO.20.00257 (2020).","journal-title":"JCO Precis. Oncol."},{"key":"3282_CR18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","volume":"9","author":"N Cook","year":"2016","unstructured":"Cook, N. et al. Early phase clinical trials to identify optimal dosing and safety. Mol. Oncol. 9, 997\u20131007 (2016).","journal-title":"Mol. Oncol."},{"key":"3282_CR19","first-page":"14","volume":"1","author":"Y Yuan","year":"2022","unstructured":"Yuan, Y. & Chen, K. Novel Bayesian adaptive early phase designs to accelerate the development of CAR T-cell therapy. Hematol. Oncol. Discov. 1, 14\u201323 (2022).","journal-title":"Hematol. Oncol. Discov."},{"key":"3282_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan, J. et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood 135, 387\u2013391 (2020).","journal-title":"Blood"},{"key":"3282_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 10, 15 (2020).","journal-title":"Blood Cancer J."},{"key":"3282_CR22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins","year":"1997","unstructured":"Collins, R. H. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433\u2013444 (1997).","journal-title":"J. Clin. Oncol."},{"key":"3282_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","volume":"29","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy. Transplant. Cell. Ther. 29, 167\u2013173 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"3282_CR24","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3282_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138, 11\u201322 (2021).","journal-title":"Blood"},{"key":"3282_CR26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med."},{"key":"3282_CR27","doi-asserted-by":"crossref","first-page":"640166","DOI":"10.3389\/fonc.2021.640166","volume":"11","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. Short-interval sequential CAR-T cell infusion may enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL. Front. Oncol. 11, 640166 (2021).","journal-title":"Front. Oncol."},{"key":"3282_CR28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","volume":"41","author":"AW Loren","year":"2008","unstructured":"Loren, A. W. & Porter, D. L. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone. Marrow. Transplant. 41, 483\u2013493 (2008).","journal-title":"Bone. Marrow. Transplant."},{"key":"3282_CR29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni, A. et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am. J. Hematol. 95, 1466\u20131472 (2020).","journal-title":"Am. J. Hematol."},{"key":"3282_CR30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3282_CR31","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan, J. et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia 34, 3382\u20133387 (2020).","journal-title":"Leukemia"},{"key":"3282_CR32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3282_CR33","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain, N. et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood 127, 1863\u20131869 (2016).","journal-title":"Blood"},{"key":"3282_CR34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood. Marrow. Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood. Marrow. Transplant."},{"key":"3282_CR35","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka, D. et al. 1994 Consensus Conference on acute GVHD grading. Bone. Marrow. Transplant. 15, 825\u2013828 (1995).","journal-title":"Bone. Marrow. Transplant."},{"key":"3282_CR36","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 (National Cancer Institute, 2017); https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"3282_CR37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan, J. et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 24, 1229\u20131241 (2023).","journal-title":"Lancet Oncol."},{"key":"3282_CR38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner, R. A. et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 134, 2149\u20132158 (2019).","journal-title":"Blood."},{"key":"3282_CR39","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127, 2391\u20132405 (2016).","journal-title":"Blood."},{"key":"3282_CR40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"PA Brown","year":"2021","unstructured":"Brown, P. A. et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 19, 1079\u20131109 (2021).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"3282_CR41","doi-asserted-by":"crossref","unstructured":"Carreras, E. et al. (eds) The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies (Springer, 2019).","DOI":"10.1007\/978-3-030-02278-5"},{"key":"3282_CR42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbrc.2020.12.012","volume":"534","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem. Biophys. Res. Commun. 534, 149\u2013156 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3282_CR43","first-page":"4643","volume":"22","author":"K Wang","year":"2018","unstructured":"Wang, K. et al. Measurements of T-cell receptor excision cycles in early stage of immune reconstitution after hematopoietic stem cell transplantation. Chin. J. Tissue Eng. Res. 22, 4643\u20134649 (2018).","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"3282_CR44","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"3282_CR45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fimmu.2015.00287","volume":"6","author":"Y Peng","year":"2015","unstructured":"Peng, Y. et al. Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus vaccination. Front. Immunol. 6, 287 (2015).","journal-title":"Front. Immunol."}],"updated-by":[{"DOI":"10.1038\/s41591-024-03348-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03282-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03282-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03282-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:04:07Z","timestamp":1737500647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03282-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03282-2","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-024-03348-1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03348-1","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03348-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.H. and T.T. are employees of Nanjing IASO Biotherapeutics Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}